Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Saxagliptin
Drug ID BADD_D01992
Description Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Indications and Usage Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.
Marketing Status Prescription
ATC Code A10BH03
DrugBank ID DB06335
KEGG ID D08996
MeSH ID C502994
PubChem ID 11235729
TTD Drug ID D0K9MY
NDC Product Code 0310-6105; 55154-6931; 11722-078; 0310-6100; 50370-0030; 50193-4212
Synonyms saxagliptin | 3-hydroxyadamantylglycine-4,5-methanoprolinenitrile hydrate | Onglyza | BMS 477118 | BMS477118 | BMS-477118
Chemical Information
Molecular Formula C18H25N3O2
CAS Registry Number 361442-04-8
SMILES C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cardiac failureDipeptidyl peptidase 4P27487T3139125453730
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest discomfort02.02.02.009; 22.02.08.001; 08.01.08.0190.001500%Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.0110.003001%Not Available
Chills15.05.03.016; 08.01.09.0010.001500%
Cholecystitis09.03.01.0010.001500%
Cholelithiasis09.03.01.0020.003001%Not Available
Circulatory collapse24.06.02.0010.001500%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Death08.04.01.001--
Dehydration14.05.05.0010.003001%
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.0040.003001%Not Available
Diarrhoea07.02.01.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.001500%Not Available
Dysgeusia17.02.07.003; 07.14.03.0010.001500%
Dyspepsia07.01.02.0010.001500%
Dysphagia07.01.06.0030.005251%
Dyspnoea22.02.01.004; 02.01.03.002--
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flatulence07.01.04.002--
Fluid retention20.01.02.003; 14.05.06.0020.002251%Not Available
Fracture15.08.02.001; 12.04.02.001--
Gait disturbance17.02.05.016; 08.01.02.0020.001500%
Gamma-glutamyltransferase increased13.03.01.0110.003001%
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages